University of Dundee
Welcome,         Profile    Billing    Logout  
 15 Trials 
13 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MacDonald, Thomas M
OUTREACH, NCT03293147: Urine Analysis and Antihypertensive Treatment

Completed
N/A
200
Europe
HPLC-MS/MS-guided intervention, Standard care
University of Manchester, British Heart Foundation, Manchester Academic Health Science Centre, Omron Healthcare Co., Ltd.
Hypertension, Adherence, Medication
08/23
09/23
Lang, Chim
GOAL-HF1, NCT05642507: Phase Ib/IIa Trial With AC01 in Patients With HFrEF

Recruiting
1/2
80
Europe
AC01
AnaCardio AB
Heart Failure With Reduced Ejection Fraction
06/25
06/25
George, Jacob
B-Well 2, NCT05630820 / 2022-002268-53: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B

Active, not recruiting
3
871
Europe, Canada, Japan, US, RoW
Bepirovirsen, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Chronic Hepatitis B, Hepatitis B, Chronic
11/25
05/26
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Recruiting
2
280
Europe, Canada, Japan, US, RoW
Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo
GlaxoSmithKline
Chronic Hepatitis B Virus Infection, Hepatitis B
10/27
10/27
Dillon, John
SARCA, NCT05339139: SAfety of Regional Citrate Anticoagulation ( Study)

Recruiting
3
50
US
Dialysis
Fresenius Medical Care North America
Acute Kidney Injury, ESRD
11/24
03/25
Chalmers, James D
MAHALE, NCT05006573 / 2020-004068-24: Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis

Hourglass Nov 2024 - Dec 2024 : Regulatory decision in Japan for eosinophilic granulomatosis with polyangiitis
Completed
3
100
Europe, Canada, US, RoW
Benralizumab, Placebo to Benralizumab
AstraZeneca
Non-cystic Fibrosis Bronchiectasis
04/24
04/24
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
VitalBE, NCT03696290 / 2018-001590-24: Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis

Recruiting
2
77
Europe
Aztreonam lysine, Cayston, Placebo, Lactose monohydrate
University of Dundee, Gilead Sciences
Bronchiectasis Adult
09/25
09/25
NCT06166056: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

Recruiting
1/2
45
Europe
CHF6333, CHF6333 Placebo
Chiesi Farmaceutici S.p.A.
Bronchiectasis
06/25
06/25
Sammler, Esther
LIGHTHOUSE, NCT05418673 / 2022-000747-77: A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

Terminated
3
7
Europe, US
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
07/23
07/23
LUMA, NCT05348785 / 2021-004849-20: A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

Recruiting
2
640
Europe, Canada, Japan, US, RoW
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
12/25
12/25
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

Active, not recruiting
2
237
Europe, Canada, US
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Bial R&D Investments, S.A.
Parkinson's Disease
03/26
07/26
ROPAD, NCT03866603: Rostock International Parkinson's Disease Study

Active, not recruiting
N/A
25000
Europe, Canada, US, RoW
CENTOGENE GmbH Rostock
Parkinson´s Disease
12/25
12/25

Download Options